Literature DB >> 24287791

Transcription factor Ets-1 inhibits glucose-stimulated insulin secretion of pancreatic β-cells partly through up-regulation of COX-2 gene expression.

Xiong-Fei Zhang1, Yi Zhu, Wen-Biao Liang, Jing-Jing Zhang.   

Abstract

Increased cyclooxygenase-2 (COX-2) expression is associated with pancreatic β-cell dysfunction. We previously demonstrated that the transcription factor Ets-1 significantly up-regulated COX-2 gene promoter activity. In this report, we used the pancreatic β-cell line INS-1 and isolated rat islets to investigate whether Ets-1 could induce β-cell dysfunction through up-regulating COX-2 gene expression. We investigated the effects of ETS-1 overexpression and the effects of ETS-1 RNA interference on endogenous COX-2 expression in INS-1 cells. We used site-directed mutagenesis and a dual luciferase reporter assay to study putative Ets-1 binding sites in the COX-2 promoter. The effect of ETS-1 1 overexpression on the insulin secretion function of INS-1 cells and rat islets and the potential reversal of these effects by a COX-2 inhibitor were determined in a glucose-stimulated insulin secretion (GSIS) assay. ETS-1 overexpression significantly induces endogenous COX-2 expression, but ETS-1 RNA interference has no effect on basal COX-2 expression in INS-1 cells. Ets-1 protein significantly increases COX-2 promoter activity through the binding site located in the -195/-186 region of the COX-2 promoter. ETS-1 overexpression significantly inhibited the GSIS function of INS-1 cells and islet cells and COX-2 inhibitor treatment partly reversed this effect. These findings indicated that ETS-1 overexpression induces β-cell dysfunction partly through up-regulation of COX-2 gene expression. Moreover, Ets-1, the transcriptional regulator of COX-2 expression, may be a potential target for the prevention of β-cell dysfunction mediated by COX-2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24287791     DOI: 10.1007/s12020-013-0114-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  35 in total

Review 1.  Signal transduction and the Ets family of transcription factors.

Authors:  J S Yordy; R C Muise-Helmericks
Journal:  Oncogene       Date:  2000-12-18       Impact factor: 9.867

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Overexpression of cyclooxygenase-2 in NCI-H292 human alveolar epithelial carcinoma cells: roles of p38 MAPK, ERK-1/2, and PI3K/PKB signaling proteins.

Authors:  Suhaeng Sung; Yukyoung Park; Jeong-Rang Jo; Nak-Kyun Jung; Dae-Kyu Song; Jaehoon Bae; Dong-Yun Keum; Jae-Bum Kim; Gy-Young Park; Byeong-Churl Jang; Jong-Wook Park
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

4.  COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice.

Authors:  T Tabatabaie; A M Waldon; J M Jacob; R A Floyd; Y Kotake
Journal:  Biochem Biophys Res Commun       Date:  2000-07-05       Impact factor: 3.575

5.  Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.

Authors:  Phuong Oanh T Tran; Catherine E Gleason; R Paul Robertson
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

6.  Cyclooxygenase-2-derived prostacyclin protective role on endotoxin-induced mouse cardiomyocyte mortality.

Authors:  Maria Antonietta Panaro; Maria Pricci; Ferhat Meziani; Thierry Ragot; Ramaroson Andriantsitohaina; Vincenzo Mitolo; Angela Tesse
Journal:  Cardiovasc Toxicol       Date:  2011-12       Impact factor: 3.231

Review 7.  Cyclooxygenases: structural and functional insights.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

8.  Inhibition of forkhead box O1 protects pancreatic beta-cells against dexamethasone-induced dysfunction.

Authors:  Xiongfei Zhang; Wei Yong; Jinghuan Lv; Yunxia Zhu; Jingjing Zhang; Fang Chen; Rihua Zhang; Tao Yang; Yujie Sun; Xiao Han
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

9.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

Authors:  M Tsujii; S Kawano; R N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Flavonoids targeting of IκB phosphorylation abrogates carcinogen-induced MMP-9 and COX-2 expression in human brain endothelial cells.

Authors:  Elizabeth Tahanian; Luis Arguello Sanchez; Tze Chieh Shiao; René Roy; Borhane Annabi
Journal:  Drug Des Devel Ther       Date:  2011-05-13       Impact factor: 4.162

View more
  4 in total

1.  Ets-1 as an early response gene against hypoxia-induced apoptosis in pancreatic β-cells.

Authors:  N Qiao; C Xu; Y-X Zhu; Y Cao; D-C Liu; X Han
Journal:  Cell Death Dis       Date:  2015-02-19       Impact factor: 8.469

2.  INFIMA leverages multi-omics model organism data to identify effector genes of human GWAS variants.

Authors:  Chenyang Dong; Shane P Simonett; Sunyoung Shin; Donnie S Stapleton; Kathryn L Schueler; Gary A Churchill; Leina Lu; Xiaoxiao Liu; Fulai Jin; Yan Li; Alan D Attie; Mark P Keller; Sündüz Keleş
Journal:  Genome Biol       Date:  2021-08-23       Impact factor: 17.906

3.  Transcription factor Ets1 regulates expression of thioredoxin-interacting protein and inhibits insulin secretion in pancreatic β-cells.

Authors:  Yan Luo; Fengli He; Li Hu; Luo Hai; Meifeng Huang; Zhipeng Xu; Jingjing Zhang; Zhiguang Zhou; Feng Liu; Yan-Shan Dai
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

4.  EGF suppresses the expression of miR-124a in pancreatic β cell lines via ETS2 activation through the MEK and PI3K signaling pathways.

Authors:  Lin Yang; Yuansen Zhu; Delin Kong; Jiawei Gong; Wen Yu; Yang Liang; Yuzhe Nie; Chun-Bo Teng
Journal:  Int J Biol Sci       Date:  2019-09-07       Impact factor: 6.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.